The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness

High Altitude Medicine and Biology

Volumn 16, Issue 4, 2015, Pages 318-330

  Su, Juan ^a   Li, Zhanquan ^a   Cui, Sen ^a   Ji, Linhua ^a   Geng, Hui ^a   Chai, Kexia ^a   Ma, Xiaojing ^a   Bai, Zhenzhong ^a   Yang, Yingzhong ^a   Wuren, Tana ^a   Ge, Ri Li ^a   Rondina, Matthew T ^b  

^a QINGHAI UNIVERSITY   (China)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

bone marrow cells; chronic; erythropoietin; hypoxia inducible factors; microvessel density; mountain sickness

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ADULT; ALTITUDE DISEASE; ARTICLE; BLOOD PRESSURE; BODY MASS; BONE MARROW; BONE MARROW CELL; CAPILLARY DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; FEMALE; FLOW CYTOMETRY; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUPERNATANT; THROMBOCYTE COUNT; ALTITUDE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; METABOLISM; MICROVASCULATURE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; POLYCYTHEMIA; SIGNAL TRANSDUCTION; VASCULARIZATION;

ADULT; ALTITUDE; ALTITUDE SICKNESS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE MARROW; CASE-CONTROL STUDIES; CHRONIC DISEASE; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYCYTHEMIA; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84951939589     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2015.0015     Document Type: Article

References (65)

1. Abali H, Haznedaroglu IC, Goker H, Celik I, Ozatli D, Koray Z, Caglar M. (2002). Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: Preliminary evidences. Hematology 7:75-82.
2. Adams RH, Alitalo K. (2007). Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478.
3. Appenzeller O, Minko T, Pozharov V, Bonfichi M, Malcovati L, Gamboa J, Bernardi L. (2003). Gene expression in the Andes; relevance to neurology at sea level. J Neurol Sci 207:37-41.
4. Appenzeller O, Minko T, Qualls C, Pozharov V, Gamboa J, Gamboa A, Wang Y. (2006). Gene expression, autonomic function and chronic hypoxia: Lessons from the Andes. Clin Auton Res 16:217-222.
5. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. (2004). Erythropoietin regulates endothelial progenitor cells. Blood 103:921-926.
6. Beall C, Cavalleri G, Deng L, Elston R, Gao Y, Knight J, Li C, Li J, Liang Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wangdui P, Weale ME, Xu Y, Xu Z, Yang L, Zaman MJ, Zeng C, Zhang L, Zhang X, Zhaxi P, Zheng YT. (2010). Natural selection on EPAS1 (HIF2a) associated with low hemoglobin concentration in Tibetan highlanders. Proc Nat Acad Sci USA 107:11459-11464.
7. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. (2004). Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073-2080.
8. Bennis Y, Sarlon-Bartoli G, Guillet B, Lucas L, Pellegrini L, Velly L, Blot-Chabaud M, Dignat-Georges F, Sabatier F, Pisano P. (2012). Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost 10:1914-1928.
9. Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, Keren G, George J. (2008). Constitutive expression of HIF-1a and HIF-2a in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells 26:2634-2643.
10. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. (2000). Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60:7106-7113.
11. Buroker NE, Ning XH, Zhou ZN, Li K, Cen WJ, Wu XF, Zhu WZ, Scott CR, Chen SH. (2012). AKT3, ANGPTL4, eNOS3, VEGFA associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau. Int J Hematol 96:200-213.
12. Buroker NE, Ning XH, Zhou ZN, Li K, Cen WJ, Wu XF, Zhu WZ, Scott CR, Chen SH. (2013). VEGFA SNPs and transcriptional factor binding sites associated with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau. J Physiol Sci 63:183-193.
13. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. (2011) Why is the partial oxygen pressure of human tissues a crucial parameter Small molecules and hypoxia. J Cell Mol Med 15:1239-1253.
14. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LEH. (2009). Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 50:1329-1335.
15. Cheng J, Kang X, Zhang S, Yeh ET. (2007). SUMOspecific protease 1 is essential for stabilization of HIF1a during hypoxia. Cell 131:584-595.
16. Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, Noguchi CT. (2000). Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 81:29-42.
17. Cole AM, Petousi N, Cavalleri GL, Robbins PA. (2014). Genetic variation in SENP1 and ANP32D as predictors of chronic mountain sickness. High Alt Med Biol 15:497-499.
18. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, Harris AL. (1997). Targeting gene expression to hypoxic tumor cells. Nat Med 3:515-520.
19. Espinoza JR, Alvarez G, León-Velarde F, Preciado HF, Macarlupu JL, Rivera-Ch M, Rodriguez J, Favier J, Gimenez-Roqueplo AP, Richalet JP. (2014). Vascular endothelial growth factor-A is associated with chronic mountain sickness in the Andean population. High Alt Med Biol 15:146-154
20. Fandrey J. (2004). Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286:R977-R988.
21. Furlow PW, Percy MJ, Sutherland S, Bierl C, McMullin MF, Master SR, Lappin TR, Lee FS. (2009). Erythrocytosisassociated HIF-2a mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 284:9050-9058.
22. Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. (2008). Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2a mutation. Blood 112:919-921.
23. Ge RL, Mo VY, Januzzi JL, Jin G, Yang Y, Han S, Wood MJ, Levine BD. (2011). B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1 and nitric oxide synthase in chronic mountain sickness. Am J Physiol Heart Circ Physiol 300:H1427-H1433.
24. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. (2007). HIF-2a promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11:335-347.
25. Haase VH. (2013). Regulation of erythropoiesis by hypoxiainducible factors. Blood Rev 27:41-53.
26. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L, Pa°hlman S. (2006). Recruitment of HIF-1a and HIF-2a to common target genes is differentially regulated in neuroblastoma: HIF-2a promotes an aggressive phenotype. Cancer Cell 10:413-423.
27. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. (2002). Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326-333.
28. Jiang CH, Chen J, Liu FY, Luo YJ, Xu G, Shen HY, Gao YQ, Gao WX. (2014). Chronic mountain sickness in Chinese Han males who migrated to the Qinghai-Tibetan plateau: Application and evaluation of diagnostic criteria for chronic mountain sickness. BMC Public Health 14:701.
29. Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL, Haase VH. (2010). Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116:3039-3048.
30. Koh MY, Lemos R, Jr., Liu X, Powis G. (2011). The hypoxia-associated factor switches cells from HIF-1a-to HIF-2a-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71:4015-4027.
31. Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM, Terpos E, Stamatopoulos K, Plata E, Anargyrou K,roulaki A, Davaris P, Yataganas X. (2003). Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: A morphometric study. Leukemia 17:89-97.
32. León-Velarde F, Arregui A, Vargas M, Huicho L, Acosta R. (1994). Chronic mountain sickness and chronic lower respiratory tract infections. Chest 106:151-155.
33. León-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, Ge RL, Hackett P, Kobayashi T, Moore LG, Penaloza D, Richalet JP, Roach R, Wu T, Vargas E, Zubieta-Castillo G, Zubieta-Calleja G. (2005). Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 6:147-157.
34. León-Velarde F, McCullough RG, McCullough RE, Reeves JT; CMS Consensus Working Group. (2003). Proposal for scoring severity in chronic mountain sickness (CMS). Background and conclusions of the CMS Working Group. Adv Exp Med Biol 543:339-354.
35. León-Velarde F, Monge C, Vidal A, Carcagno M, Criscuolo M, Bozzini CE. (1991). Serum immunoreactive erythropoietin in high altitude natives with and without excessive erythrocytosis. Exp Hematol 19:257-260.
36. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. (2010). Macrophages as novel target cells for erythropoietin. Haematologica 95:1823-1831.
37. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 25:402-408.
38. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L. (2001). Inhibitory PAS domain protein is a negative regulator of hypoxiainducible gene expression. Nature 414:550-554.
39. Martini M, Teofili L, Cenci T, Giona F, Torti L, Rea M, Foà R, Leone G, Larocca LM. (2008). A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 93:1068-1071.
40. Mejá OM, Prchal JT, León-Velarde F, Hurtado A, Stockton DW. (2005). Genetic association analysis of chronic mountain sickness in an Andean high-altitude population. Haematologica. 90. 13-19.
41. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, Fujii-Kuriyama Y. (2003). HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22:1134-1146.
42. Penaloza D, Arias-Stella J. (2007). The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness. Circulation 115:1132-1146.
43. Percy MJ, Beer PA, Campbell G, Dekker AW, Green AR, Oscier D, Rainey MG, van Wijk R, Wood M, Lappin TR, McMullin MF, Lee FS. (2008a). Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111:5400-5402.
44. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, Lee FS. (2008b). A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358:162-168.
45. Rankin EB, Wu C, Khatri R, Wilson TL,ersen R, Araldi E, Rankin AL, Yuan J, Kuo CJ, Schipani E, Giaccia AJ. (2012). The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149:63-74.
46. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU. (2002). Expression of hypoxia-inducible factor-1alpha and-2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13:1721-1732.
47. Sato T, Maekawa T, Watanabe S, Tsuji K, Nakahata T. (2000). Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 106:263-270.
48. Scortegagna M, Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M, Shelton JM, Richardson JA, Moe O, Garcia JA. (2005). HIF-2 alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105:3133-3140.
49. Semenza GL, Wang GL. (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454.
50. Simonson TS, Yang Y, Huff C, Yun H, Qin G, Witherspoon D, Bai Z, Lorenzo F, Xing J, Jorde LB, Prchal JT, Ge R. (2010). Genetic evidence for high-altitude adaptation in Tibet. Science 329:72-75.
51. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, Iruela-Arispe L, Simon MC, Keith B. (2009). Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 114:469-477.
52. Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, Runge A, Liu L, Kim MN, Liang J, Schenkel S, Yodh AG, Keith B, Simon MC. (2012). Endothelial HIF-2a regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 122:1427-1443.
53. Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. (1998). Human hematopoietic progenitors express erythropoietin. Blood 91:3766-3772.
54. Tian H, Mcknight SL, Russer DW. (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72-82.
55. Villafuerte FC, Macarlupú JL, Anza-Ramrez C, Corrales-Melgar D, Vizcardo-Galindo G, Corante N, León-Velarde F. (2014). J Appl Physiol 117:1356-1362.
56. Wang GL, Jing BH, Rue EA, Semenza GL. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510-5514.
57. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. (2004). Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35:1732-1737.
58. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. (2004). Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18:1462-1464.
59. Weidemann A, Johnson RS. (2009). Nonrenal regulation of EPO synthesis. Kidney Int 75:682-688.
60. Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU. (2003). Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17:271-273.
61. Yeo EJ, Cho YS, Kim MS, Park JW. (2008). Contribution of HIF-1alpha or HIF-2alpha to erythropoietin expression: In vivo evidence based on chromatin immunoprecipitation. Ann Hematol 87:11-17.
62. Yi X, Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, Xu X, Jiang H, Vinckenbosch N, Korneliussen TS, Zheng H, Liu T, He W, Li K, Luo R, Nie X, Wu H, Zhao M, Cao H, Zou J, Shan Y, Li S, Yang Q, Asan, Ni P, Tian G, Xu J, Liu X, Jiang T, Wu R, Zhou G, Tang M, Qin J, Wang T, Feng S, Li G, Huasang, Luosang J, Wang W, Chen F, Wang Y, Zheng X, Li Z, Bianba Z, Yang G, Wang X, Tang S, Gao G, Chen Y, Luo Z, Gusang L, Cao Z, Zhang Q, Ouyang W, Ren X, Liang H, Zheng H, Huang Y, Li J, Bolund L, Kristiansen K, Li Y, Zhang Y, Zhang X, Li R, Li S, Yang H, Nielsen R, Wang J, Wang J. (2010). Sequencing of 50 human exomes reveals adaptation to high altitude. Science 329:75-78.
63. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A, Prchal JT. (2006). Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 281:25703-25711.
64. Yu L, Ji W, Zhang H, Renda MJ, He Y, Lin S, Cheng EC, Chen H, Krause DS, Min W. (2010). SENP1-mediated GATA1 de SUMOylation is critical for definitive erythropoiesis. J Exp Med 207:1183-1195.
65. Zhou D, Udpa N, Ronen R, Stobdan T, Liang J, Appenzeller O, Zhao HW, Yin Y, Du Y, Guo L, Cao R, Wang Y, Jin X, Huang C, Jia W, Cao D, Guo G, Gamboa JL, Villafuerte F, Callacondo D, Xue J, Liu S, Frazer KA, Li Y, Bafna V, Haddad GG. (2013). Whole-genome sequencing uncovers the genetic basis of chronic mountain sickness in Andean highlanders. Am J Hum Genet 93:452-462.